| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 34 | 2021 | 745 | 5.270 |
Why?
|
| Echocardiography, Transesophageal | 14 | 2020 | 262 | 2.730 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 15 | 2012 | 87 | 2.710 |
Why?
|
| Guideline Adherence | 12 | 2020 | 236 | 2.490 |
Why?
|
| Cardiology | 10 | 2021 | 120 | 2.360 |
Why?
|
| Image Enhancement | 10 | 2012 | 505 | 1.650 |
Why?
|
| Practice Guidelines as Topic | 12 | 2016 | 1053 | 1.620 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 751 | 1.590 |
Why?
|
| Heart Diseases | 8 | 2018 | 257 | 1.530 |
Why?
|
| Exercise Test | 10 | 2021 | 152 | 1.490 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2014 | 626 | 1.360 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2007 | 258 | 1.260 |
Why?
|
| American Heart Association | 6 | 2020 | 106 | 1.240 |
Why?
|
| Inpatients | 2 | 2021 | 345 | 1.080 |
Why?
|
| Algorithms | 8 | 2014 | 1953 | 1.040 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2019 | 3476 | 1.010 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2016 | 22 | 1.000 |
Why?
|
| Societies, Medical | 9 | 2016 | 621 | 0.990 |
Why?
|
| Peripheral Vascular Diseases | 4 | 2009 | 56 | 0.990 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2018 | 163 | 0.950 |
Why?
|
| Coronary Artery Disease | 8 | 2012 | 375 | 0.890 |
Why?
|
| Heart | 5 | 2009 | 522 | 0.870 |
Why?
|
| Electrocardiography | 5 | 2018 | 493 | 0.870 |
Why?
|
| Syncope | 2 | 2021 | 29 | 0.860 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2021 | 624 | 0.850 |
Why?
|
| Humans | 107 | 2022 | 93511 | 0.830 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2012 | 38 | 0.800 |
Why?
|
| Erectile Dysfunction | 3 | 2009 | 78 | 0.750 |
Why?
|
| Myocardial Ischemia | 5 | 2008 | 140 | 0.740 |
Why?
|
| Osteoarthritis, Knee | 7 | 2019 | 71 | 0.730 |
Why?
|
| Pattern Recognition, Automated | 4 | 2014 | 217 | 0.710 |
Why?
|
| Echocardiography, Stress | 2 | 2012 | 15 | 0.700 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2020 | 145 | 0.700 |
Why?
|
| Brain | 4 | 2012 | 2391 | 0.660 |
Why?
|
| Heart Murmurs | 1 | 2020 | 6 | 0.640 |
Why?
|
| Electronic Health Records | 2 | 2021 | 372 | 0.630 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 57 | 0.630 |
Why?
|
| Protein Multimerization | 4 | 2016 | 191 | 0.630 |
Why?
|
| Advisory Committees | 3 | 2015 | 90 | 0.600 |
Why?
|
| Diazomethane | 1 | 2018 | 5 | 0.580 |
Why?
|
| Sensitivity and Specificity | 15 | 2012 | 1922 | 0.580 |
Why?
|
| Unnecessary Procedures | 3 | 2021 | 42 | 0.560 |
Why?
|
| Coronary Disease | 2 | 2010 | 223 | 0.560 |
Why?
|
| Quality of Health Care | 2 | 2014 | 382 | 0.560 |
Why?
|
| Aged | 35 | 2021 | 20430 | 0.540 |
Why?
|
| Pandemics | 2 | 2021 | 873 | 0.530 |
Why?
|
| Cardiomyopathies | 4 | 2020 | 291 | 0.510 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.500 |
Why?
|
| Medicare | 1 | 2020 | 455 | 0.500 |
Why?
|
| Ischemic Attack, Transient | 3 | 2008 | 184 | 0.500 |
Why?
|
| Reproducibility of Results | 15 | 2014 | 2715 | 0.490 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 394 | 0.490 |
Why?
|
| Preoperative Care | 3 | 2021 | 406 | 0.480 |
Why?
|
| Heart Ventricles | 4 | 2019 | 650 | 0.470 |
Why?
|
| Middle Aged | 41 | 2021 | 27569 | 0.460 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2015 | 2 | 0.450 |
Why?
|
| Myocardium | 3 | 2009 | 570 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.440 |
Why?
|
| Prevalence | 7 | 2020 | 1321 | 0.440 |
Why?
|
| United States | 23 | 2021 | 7619 | 0.440 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 62 | 0.430 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 106 | 0.420 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2015 | 100 | 0.420 |
Why?
|
| Knee Injuries | 4 | 2015 | 53 | 0.420 |
Why?
|
| Male | 43 | 2021 | 44553 | 0.410 |
Why?
|
| Coronary Circulation | 4 | 2007 | 95 | 0.410 |
Why?
|
| Knee Joint | 5 | 2015 | 161 | 0.410 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 1713 | 0.410 |
Why?
|
| Nuclear Medicine | 3 | 2008 | 12 | 0.410 |
Why?
|
| Cardiac Catheterization | 2 | 2012 | 295 | 0.400 |
Why?
|
| Stroke | 3 | 2008 | 1079 | 0.380 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2003 | 45 | 0.370 |
Why?
|
| Health Services Misuse | 1 | 2012 | 20 | 0.370 |
Why?
|
| Health Policy | 1 | 2014 | 206 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2021 | 1090 | 0.350 |
Why?
|
| Female | 42 | 2021 | 48698 | 0.340 |
Why?
|
| Blood Pressure | 3 | 2010 | 896 | 0.330 |
Why?
|
| Exercise | 2 | 2019 | 353 | 0.330 |
Why?
|
| Diagnostic Imaging | 4 | 2016 | 452 | 0.320 |
Why?
|
| Radiopharmaceuticals | 4 | 2020 | 203 | 0.310 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 107 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2021 | 4560 | 0.310 |
Why?
|
| Risk Assessment | 10 | 2021 | 2440 | 0.310 |
Why?
|
| Heart Rate | 2 | 2010 | 505 | 0.310 |
Why?
|
| Risk Factors | 15 | 2019 | 5898 | 0.310 |
Why?
|
| Utilization Review | 3 | 2020 | 23 | 0.300 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 138 | 0.300 |
Why?
|
| Logistic Models | 8 | 2014 | 1243 | 0.300 |
Why?
|
| Brachial Artery | 1 | 2009 | 37 | 0.300 |
Why?
|
| Ankle | 1 | 2009 | 27 | 0.290 |
Why?
|
| Coronary Angiography | 2 | 2012 | 231 | 0.290 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 69 | 0.290 |
Why?
|
| Internet | 1 | 2011 | 337 | 0.280 |
Why?
|
| Embolism | 1 | 2008 | 32 | 0.280 |
Why?
|
| Heart Atria | 2 | 2007 | 248 | 0.280 |
Why?
|
| HEK293 Cells | 5 | 2018 | 696 | 0.280 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2007 | 112 | 0.280 |
Why?
|
| Patient Selection | 2 | 2010 | 690 | 0.280 |
Why?
|
| Community Health Centers | 1 | 2009 | 119 | 0.280 |
Why?
|
| Ambulatory Care | 1 | 2009 | 193 | 0.270 |
Why?
|
| Pulmonary Embolism | 2 | 2008 | 226 | 0.270 |
Why?
|
| Organotechnetium Compounds | 2 | 2007 | 10 | 0.270 |
Why?
|
| Organophosphorus Compounds | 2 | 2007 | 46 | 0.260 |
Why?
|
| Menisci, Tibial | 2 | 2019 | 26 | 0.260 |
Why?
|
| Carotid Arteries | 1 | 2008 | 131 | 0.260 |
Why?
|
| Documentation | 2 | 2021 | 97 | 0.260 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1103 | 0.260 |
Why?
|
| Thrombosis | 2 | 2007 | 309 | 0.250 |
Why?
|
| Contrast Media | 5 | 2008 | 988 | 0.250 |
Why?
|
| Bone Marrow | 3 | 2013 | 409 | 0.250 |
Why?
|
| Endocardium | 2 | 2004 | 78 | 0.250 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2006 | 5 | 0.250 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 985 | 0.250 |
Why?
|
| Myocardial Stunning | 1 | 2006 | 10 | 0.240 |
Why?
|
| Hospitalization | 1 | 2012 | 937 | 0.240 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2006 | 6 | 0.240 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 383 | 0.230 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 42 | 0.230 |
Why?
|
| Hypertension | 2 | 2010 | 757 | 0.230 |
Why?
|
| Adult | 19 | 2021 | 27918 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1261 | 0.220 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 176 | 0.220 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 520 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 1917 | 0.210 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 106 | 0.210 |
Why?
|
| Prognosis | 7 | 2019 | 3910 | 0.210 |
Why?
|
| Anemia, Hemolytic | 2 | 2004 | 17 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 150 | 0.210 |
Why?
|
| Cartilage, Articular | 2 | 2015 | 77 | 0.210 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2004 | 18 | 0.210 |
Why?
|
| Mass Screening | 1 | 2009 | 696 | 0.210 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 6 | 0.210 |
Why?
|
| Brain Ischemia | 1 | 2008 | 414 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 7061 | 0.210 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 425 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2021 | 10164 | 0.210 |
Why?
|
| Aortic Diseases | 1 | 2004 | 87 | 0.210 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 27 | 0.200 |
Why?
|
| Ischemia | 1 | 2005 | 253 | 0.200 |
Why?
|
| Thallium | 1 | 2003 | 5 | 0.200 |
Why?
|
| Aortic Valve Stenosis | 1 | 2005 | 147 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 333 | 0.200 |
Why?
|
| Time Factors | 8 | 2019 | 5410 | 0.200 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 53 | 0.200 |
Why?
|
| Point-of-Care Systems | 2 | 2020 | 150 | 0.200 |
Why?
|
| Radionuclide Imaging | 2 | 2016 | 189 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 83 | 0.190 |
Why?
|
| Clinical Competence | 3 | 2021 | 822 | 0.190 |
Why?
|
| Schools, Nursing | 1 | 2002 | 1 | 0.190 |
Why?
|
| Perioperative Nursing | 1 | 2002 | 1 | 0.190 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 52 | 0.190 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2802 | 0.190 |
Why?
|
| Inservice Training | 1 | 2002 | 36 | 0.190 |
Why?
|
| Angina Pectoris | 1 | 2002 | 20 | 0.190 |
Why?
|
| Mitral Valve | 2 | 2004 | 225 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2022 | 378 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2022 | 52 | 0.180 |
Why?
|
| Coronary Vessels | 1 | 2003 | 178 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 394 | 0.180 |
Why?
|
| Radiology | 2 | 2016 | 192 | 0.180 |
Why?
|
| Hospitals | 2 | 2021 | 328 | 0.170 |
Why?
|
| Age Distribution | 3 | 2010 | 206 | 0.170 |
Why?
|
| Laboratories | 1 | 2021 | 46 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2001 | 20 | 0.170 |
Why?
|
| Abdomen | 1 | 2021 | 120 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2001 | 40 | 0.170 |
Why?
|
| Receptors, Cell Surface | 2 | 2013 | 292 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 96 | 0.160 |
Why?
|
| Family Practice | 1 | 2001 | 73 | 0.160 |
Why?
|
| Physical Examination | 2 | 2020 | 144 | 0.160 |
Why?
|
| Data Collection | 3 | 2011 | 370 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2020 | 92 | 0.160 |
Why?
|
| Periodicals as Topic | 2 | 2012 | 168 | 0.160 |
Why?
|
| Disease Progression | 4 | 2019 | 1531 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 149 | 0.150 |
Why?
|
| Mobile Applications | 1 | 2021 | 78 | 0.150 |
Why?
|
| Angiography | 2 | 2012 | 192 | 0.150 |
Why?
|
| Synovitis | 1 | 2019 | 14 | 0.150 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2019 | 10 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 306 | 0.150 |
Why?
|
| Hip Joint | 1 | 2019 | 56 | 0.150 |
Why?
|
| Atropine | 2 | 2016 | 53 | 0.150 |
Why?
|
| Accelerometry | 1 | 2019 | 48 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2021 | 99 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 111 | 0.150 |
Why?
|
| Radiation Protection | 2 | 2016 | 27 | 0.150 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2009 | 11 | 0.150 |
Why?
|
| Hospitals, University | 2 | 2010 | 188 | 0.150 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2018 | 8 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 125 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 172 | 0.140 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2019 | 48 | 0.140 |
Why?
|
| Muscarinic Antagonists | 2 | 2016 | 59 | 0.140 |
Why?
|
| Substance P | 1 | 2018 | 62 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 104 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 349 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 1910 | 0.140 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 104 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2021 | 2562 | 0.140 |
Why?
|
| Cell Membrane | 2 | 2018 | 664 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 108 | 0.140 |
Why?
|
| Age Factors | 4 | 2015 | 1906 | 0.140 |
Why?
|
| Curriculum | 1 | 2002 | 594 | 0.140 |
Why?
|
| Receptor, Muscarinic M3 | 2 | 2015 | 11 | 0.140 |
Why?
|
| Databases, Factual | 5 | 2021 | 1006 | 0.140 |
Why?
|
| Communication | 1 | 2021 | 434 | 0.130 |
Why?
|
| Incidence | 4 | 2016 | 1701 | 0.130 |
Why?
|
| Stroke Volume | 3 | 2021 | 438 | 0.130 |
Why?
|
| Ligands | 1 | 2018 | 476 | 0.130 |
Why?
|
| Perfusion | 2 | 2009 | 260 | 0.130 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 5 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2016 | 12 | 0.120 |
Why?
|
| Illinois | 3 | 2008 | 520 | 0.120 |
Why?
|
| Heart Failure | 2 | 2011 | 1386 | 0.120 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Pirenzepine | 1 | 2016 | 6 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2585 | 0.120 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 36 | 0.120 |
Why?
|
| Trastuzumab | 1 | 2016 | 86 | 0.120 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 19 | 0.110 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2015 | 6 | 0.110 |
Why?
|
| Endoscopy | 1 | 2019 | 366 | 0.110 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 100 | 0.110 |
Why?
|
| Aftercare | 1 | 2016 | 89 | 0.110 |
Why?
|
| Protein Transport | 2 | 2015 | 438 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 1546 | 0.110 |
Why?
|
| Sex Factors | 2 | 2010 | 1105 | 0.110 |
Why?
|
| Chicago | 2 | 2009 | 1464 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2021 | 3054 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 309 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 157 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 122 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2013 | 26 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 555 | 0.100 |
Why?
|
| Molecular Probe Techniques | 1 | 2013 | 10 | 0.100 |
Why?
|
| Biotinylation | 1 | 2013 | 42 | 0.100 |
Why?
|
| Butyrates | 1 | 2013 | 56 | 0.090 |
Why?
|
| Arthralgia | 1 | 2013 | 41 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 368 | 0.090 |
Why?
|
| Thiazoles | 1 | 2013 | 124 | 0.090 |
Why?
|
| Receptors, Neuropeptide | 1 | 2012 | 9 | 0.090 |
Why?
|
| Microspheres | 2 | 2002 | 88 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2016 | 404 | 0.090 |
Why?
|
| Calibration | 1 | 2012 | 106 | 0.090 |
Why?
|
| Acute Disease | 3 | 2015 | 841 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2012 | 114 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 92 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 436 | 0.090 |
Why?
|
| Acetamides | 1 | 2011 | 26 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 3828 | 0.090 |
Why?
|
| Bone Density | 1 | 2013 | 237 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 200 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 51 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2014 | 756 | 0.080 |
Why?
|
| Diagnostic Test Approval | 1 | 2010 | 1 | 0.080 |
Why?
|
| Forecasting | 2 | 2019 | 293 | 0.080 |
Why?
|
| General Practitioners | 1 | 2010 | 10 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 485 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2010 | 38 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2011 | 145 | 0.080 |
Why?
|
| Sample Size | 1 | 2010 | 128 | 0.080 |
Why?
|
| Quality Control | 1 | 2010 | 123 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2012 | 155 | 0.080 |
Why?
|
| Radiography | 4 | 2014 | 790 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 251 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 392 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 484 | 0.070 |
Why?
|
| Reference Values | 1 | 2010 | 608 | 0.070 |
Why?
|
| Prone Position | 1 | 2009 | 61 | 0.070 |
Why?
|
| Canada | 2 | 2022 | 194 | 0.070 |
Why?
|
| Gene Expression | 1 | 2013 | 1301 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2015 | 274 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 656 | 0.070 |
Why?
|
| Observer Variation | 2 | 2014 | 570 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 77 | 0.070 |
Why?
|
| Microbubbles | 1 | 2008 | 39 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 342 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 76 | 0.070 |
Why?
|
| Embolectomy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 711 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 369 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 233 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2006 | 212 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2006 | 159 | 0.060 |
Why?
|
| ROC Curve | 1 | 2008 | 775 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 9098 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 657 | 0.060 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 19 | 0.060 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 557 | 0.060 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 228 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2005 | 61 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2008 | 375 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2005 | 1524 | 0.060 |
Why?
|
| Aneurysm | 1 | 2005 | 57 | 0.060 |
Why?
|
| Comorbidity | 2 | 2006 | 1007 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 225 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 355 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2016 | 229 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2005 | 118 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 140 | 0.050 |
Why?
|
| Gallstones | 1 | 2004 | 21 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 579 | 0.050 |
Why?
|
| Aorta | 1 | 2005 | 273 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 6 | 0.050 |
Why?
|
| Extremities | 1 | 2005 | 176 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2004 | 51 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.050 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 24 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 212 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2004 | 94 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 767 | 0.050 |
Why?
|
| Smoking | 1 | 2007 | 648 | 0.050 |
Why?
|
| Rest | 1 | 2003 | 50 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2004 | 184 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 272 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 889 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 107 | 0.050 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 104 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 179 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2005 | 256 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1161 | 0.050 |
Why?
|
| California | 1 | 2002 | 158 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 179 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 142 | 0.050 |
Why?
|
| Microcirculation | 1 | 2002 | 98 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 3110 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 89 | 0.050 |
Why?
|
| Allosteric Regulation | 2 | 2013 | 68 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 85 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2002 | 50 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 60 | 0.040 |
Why?
|
| Length of Stay | 1 | 2005 | 828 | 0.040 |
Why?
|
| Albumins | 1 | 2002 | 123 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2002 | 98 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 331 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 257 | 0.040 |
Why?
|
| Survival Rate | 1 | 2005 | 1948 | 0.040 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2004 | 332 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2001 | 43 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 38 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 3169 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2001 | 84 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2004 | 454 | 0.040 |
Why?
|
| Mitral Valve Prolapse | 1 | 2000 | 18 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 1353 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 9606 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2004 | 1415 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1931 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 962 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1077 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2001 | 713 | 0.030 |
Why?
|
| Heart Arrest | 1 | 2021 | 311 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 28155 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 3147 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 123 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 76 | 0.030 |
Why?
|
| Drug Inverse Agonism | 1 | 2015 | 3 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2015 | 4 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2015 | 4 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2015 | 32 | 0.030 |
Why?
|
| Muscarinic Agonists | 1 | 2015 | 22 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 152 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 137 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 64 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 124 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2013 | 11 | 0.020 |
Why?
|
| Enteroendocrine Cells | 1 | 2013 | 8 | 0.020 |
Why?
|
| Benzeneacetamides | 1 | 2013 | 11 | 0.020 |
Why?
|
| Lipolysis | 1 | 2013 | 24 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 364 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 119 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 59 | 0.020 |
Why?
|
| Tibia | 1 | 2013 | 80 | 0.020 |
Why?
|
| Larynx | 1 | 2012 | 35 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2012 | 123 | 0.020 |
Why?
|
| Orexin Receptors | 1 | 2012 | 1 | 0.020 |
Why?
|
| Orexins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 109 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 66 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 75 | 0.020 |
Why?
|
| Adipocytes | 1 | 2013 | 169 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 2464 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 413 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 2365 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 729 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 373 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 337 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 811 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2012 | 81 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 579 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 83 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 297 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 89 | 0.020 |
Why?
|
| Child | 2 | 2015 | 7355 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1492 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 492 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 6930 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 261 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1118 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 133 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 373 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 4072 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2850 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2005 | 36 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2005 | 90 | 0.010 |
Why?
|
| Shock | 1 | 2005 | 46 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2303 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2005 | 100 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 302 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2004 | 123 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 416 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 531 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 342 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 224 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 884 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2005 | 238 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2005 | 482 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 217 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 2220 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 457 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1866 | 0.010 |
Why?
|
| Students, Medical | 1 | 2005 | 435 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 727 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 12269 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1265 | 0.010 |
Why?
|